Key facts
- Nob Hill Therapeutics’s last known valuation is $10.0M.
- It has raised $4.0M across 1 recorded rounds; the latest was Seed Round ($1.8M) in Jul 2024.
- Notable investors include National Institutes of Health, New Mexico Angels, Desert Angels, Houston Angel Network, Lung — 13 tracked in total.
- Nob Hill Therapeutics has filed 2 Form Ds with the SEC since 2018, most recently Aug 2024 ($1.8M sold to 17 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Nob Hill Therapeutics
Funding rounds
1 roundsAbout Nob Hill Therapeutics
Developer of a dry-powder nebulizer designed to help treat severe respiratory diseases. The company's nebulizer dispenses a magnetically responsive element which results in mechanical collisions within the dispersion chamber to disperse the powder independently from the patient's inhalation force ensuring reproducible delivery, enabling patients to get their respiratory diseases treated hassle-free.
- Sector
- Healthcare
- HQ
- Albuquerque, NM, United States
- Founded
- 2017
- Employees
- 5
- Website
- nobhilltherapeutics.com/
- Ownership
- Privately Held (backing)
Nob Hill Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nob Hill Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nob Hill Therapeutics in its N-PORT filings yet. We sweep new filings monthly.